The Daily Toke

April 10, 2026

# THC & POLITICS: April 2026 Briefing

Federal cannabis policy is entering a new phase of uncertainty following a significant personnel shift at the White House. Pam Bondi's departure and Todd Blanche's arrival as a key decision-maker has left the cannabis industry and reform advocates asking whether marijuana rescheduling—long positioned as an imminent shift—will actually materialize. The early signals suggest little immediate change, but the harder question lingering over Washington is one that goes beyond scheduling: if Schedule III does arrive, who actually benefits? The incoming administration appears to be maintaining previous positions on cannabis classification, even as global drug treaty reinterpretations are fundamentally reshaping CBD policy, hemp regulation, and medical cannabis access worldwide. New interpretations of international frameworks are forcing countries to rethink their approach to hemp-derived compounds, creating a patchwork of competing regulatory philosophies that U.S. policy now must contend with on a global stage.

[THIS] IS COOL] The U.S. Army just announced a significant policy shift: starting April 20, 2026, individuals with a single cannabis possession conviction or drug paraphernalia charge will be able to enlist without requiring a waiver. This represents a meaningful recognition that cannabis-related convictions should no longer serve as automatic disqualifiers for military service—a shift that opens pathways for veterans who may later seek legal cannabis products for PTSD, chronic pain, and anxiety. Simultaneously, a new federal program launched April 1 allows certain participating care models to furnish up to $500 annually in eligible hemp-derived CBD and low-THC products for approved patients. The program triggered immediate legal challenges from anti-marijuana groups attempting to shut it down, signaling that even modest expansions of cannabis access remain politically contentious at the federal level.

💰 MONEY MOVES A $10 million payment tied to a Florida Medicaid settlement has exposed an unusual financial chain: funds moved through the Hope Florida Foundation and into two anti-drug nonprofits, then channeled into political activity. The flow of settlement dollars into political organizing reveals how cannabis policy debates are being shaped by dollars with contested origins—a reminder that the movement landscape includes both grassroots organizing and institutional money with murky connections. Meanwhile, celebrity and entrepreneur involvement continues to reshape the market: YG Marley is co-founding Young Gong with Glenmere Farms, launching April 19 in New York, while Farruko, a Puerto Rican hitmaker, is framing cannabis explicitly as medicine, resistance, and a challenge to systems of fear—positioning it as something bigger than a business opportunity.

The credibility of drug enforcement itself is under pressure. A long documented trail of corruption cases, oversight failures, and drug-war contradictions has left the DEA facing a credibility crisis, even as the agency continues to influence how cannabis is scheduled, researched, and regulated across the United States. That institutional skepticism is growing at the exact moment when Latino communities and immigrants are organizing for the first time around cannabis reform as a broader justice issue—a new national coalition launching March 31 is asserting that Latino communities have spent years shaping cannabis policy while being systematically sidelined from the rooms where power, policy, and capital actually move. Their stated mission extends beyond visibility: building organized influence at the intersection of cannabis, immigration, and economic justice.

Internationally, the landscape is shifting faster than U.S. politics can track. Uruguay, the first country to legalize adult-use cannabis over a decade ago, has now entered a new phase: the system works, but it's no longer enough to sustain the market and meet demand. India is reconsidering its own relationship with cannabis, with advocates like Ed Rosenthal arguing that the plant—long woven into Indian cultural and spiritual life—should be brought back under regulation rather than criminalization. The UK's persistent criminalization stands in sharp contrast: Gary Youds has spent nearly 20 years opening cannabis cafes in Liverpool, facing raids and jail time, refusing to stop. 🤔 THINK ABOUT IT Federal policy is moving at a glacial pace while countries worldwide are fundamentally rethinking prohibition. If Schedule III rescheduling does happen, the real question isn't whether cannabis becomes legal—it's whether American policy finally catches up to what the rest of the world is already doing.

April 10, 2026

# HEMP BAN WATCH

Regulatory turbulence is reshaping the cannabis landscape globally as new interpretations of international drug treaties collide with emerging medical access programs and persistent enforcement contradictions. 🚀 THIS IS COOL A federal program that took effect April 1, 2026, now allows certain healthcare models to furnish up to $500 annually in hemp-derived CBD and low-THC products for approved patients—a meaningful expansion of access that immediately triggered lawsuits from anti-marijuana groups seeking to shut it down. This represents genuine forward movement on medical access, even as the broader policy picture remains fractured between states that have legalized and a federal government still wrestling with Schedule I classification nearly 60 years after Nixon's Controlled Substances Act.

The contradiction is sharpening.

💰 MONEY MOVES The financial stakes are real. A $10 million payment tied to a Florida Medicaid settlement moved through the Hope Florida Foundation into anti-drug nonprofits before flowing into political channels—funds that could have been directed toward evidence-based cannabis policy research instead. Meanwhile, celebrity and corporate interest continues accelerating: YG Marley entered cannabis as co-founder and brand ambassador of Young Gong, launching April 19 in New York, while Proper Doinks partnered with High Times for future Cannabis Cup collaborations. These market movements signal mainstream normalization, even as litigation against medical access programs continues.

The veteran angle matters here. The U.S. Army announced March 31 that individuals with a single conviction for cannabis possession or drug paraphernalia can enlist without a waiver starting April 20, 2026—acknowledging that many service members use legal THC products for PTSD, chronic pain, and anxiety. When states or federal agencies restrict intoxicating hemp or THC, veterans facing limited care alternatives often turn to unregulated markets or prescription opioids. Neither outcome reflects actual harm reduction.

🤔 THINK ABOUT IT Alcohol kills roughly 95,000 Americans annually. Prescription opioids kill over 16,000. Cannabis has produced zero overdose deaths in recorded history—yet remains Schedule I while both substances remain legal and heavily marketed. Uruguay legalized adult-use cannabis over a decade ago and entered a new phase where the system demonstrably works but isn't enough to meet demand. India is reconsidering decades of criminalization of ganja, a plant long woven into the culture. Meanwhile, the United States continues filing lawsuits to block medical access programs for patients, and campaign finance records show anti-cannabis funding flowing from the very industries—alcohol, pharmaceuticals, tobacco—whose products cause measurable harm. The policy incoherence isn't accidental. It's documented.

April 10, 2026

Research scientists are increasingly documenting what cannabis plants contain and how THC—tetrahydrocannabinol, the primary psychoactive compound—actually works in the human body. The cannabis plant contains over 500 chemical substances, with at least 125 identified cannabinoids. Delta-9 THC remains the most abundant and studied form, responsible for the intoxicating effects that alter mood, thoughts, and perceptions. But the scientific picture is more nuanced than popular narratives suggest. 🚀 THIS IS COOL The FDA has approved Epidiolex, a purified CBD-derived medication, for treating seizures in rare forms of epilepsy like Lennox-Gastaut syndrome and Dravet syndrome, as well as seizures from tuberous sclerosis complex—demonstrating that cannabis-derived compounds have genuine therapeutic applications when properly isolated and tested. The agency has also approved two synthetic THC-mimicking medicines, dronabinol and nabilone, specifically for treating nausea in cancer patients undergoing chemotherapy.

The legal landscape varies dramatically across the United States, creating a patchwork that complicates research and access. Twenty-four states plus Washington D.C. have fully legalized recreational cannabis, while many others permit medical use under state-regulated programs. Seven states have decriminalized marijuana, treating possession as a civil rather than criminal matter. Meanwhile, Idaho, Kansas, South Carolina, and Wyoming maintain complete prohibition. This fragmented legal status has real consequences: veterans in prohibition states who use THC products for PTSD, chronic pain, and anxiety face limited alternatives and potentially unregulated markets, while researchers struggle to conduct large-scale studies on a Schedule I substance—a classification that has remained in place for over 50 years despite the 1970 Shafer Commission recommending decriminalization.

🤔 THINK ABOUT IT Cannabis has zero recorded overdose deaths in human history, yet remains Schedule I. Meanwhile, alcohol kills approximately 95,000 Americans annually, and prescription opioids kill over 16,000 per year. Both remain legal and widely available. The divergence between documented harm and legal classification raises fundamental questions about drug policy priorities.

Cleveland Clinic and the National Institute on Drug Abuse (NIDA) emphasize that while scientists are still studying the long-term effects of cannabis, the short-term impacts are increasingly well-documented. High-THC concentrates and oils used in vaping and dabbing can rapidly deliver large amounts of THC to the body, creating unpredictable effects—particularly concerning with edibles, which have delayed onset and higher overdose risk. How cannabis affects individuals depends on THC concentration, frequency of use, mode of consumption, previous experience, biology, and sex (women report more dizziness than men after use). The CDC notes that THC oils and concentrates often contain additives or contaminants that may be harmful, underscoring the importance of regulated markets and transparency in product composition.

💰 MONEY MOVES Medical dispensaries continue expanding in markets where cannabis is legal. Jacksonville, Florida, now hosts multiple licensed retailers including Curaleaf, which operates a dedicated location on 103rd Street with accessible parking and convenient public transit access—reflecting the normalization of cannabis retail infrastructure in states with established medical programs. This retail expansion mirrors broader economic integration as cannabis legitimizes through licensing, taxation, and quality control frameworks that simply don't exist in prohibition states.

The scientific consensus is settling into a more evidence-based position: cannabis is a plant with multiple applications, some supported by clinical evidence and others still under investigation. The outstanding questions aren't whether cannabis has effects—they clearly do—but rather which effects are therapeutic, which are harmful, which populations benefit most, and what dosing protocols maximize safety. That research can only accelerate if the federal Schedule I classification changes, permitting larger-scale studies and clearer documentation of both benefits and risks. Until then, the gap between what scientists know and what policy permits remains the real obstacle to understanding THC in science.

April 10, 2026

# Texas Cannabis News Briefing

Federal policy momentum on cannabis rescheduling appears stalled despite recent staffing changes at the Department of Justice. With Todd Blanche replacing Pam Bondi in a key position, observers initially hoped for movement on marijuana's Schedule III classification—a change that could open research pathways and reduce federal penalties. Early signals suggest the shift won't accelerate the timeline. 🤔 THINK ABOUT IT The real question haunting cannabis reform isn't whether rescheduling happens, but who actually benefits when it does. Small operators and patients in prohibition states may see little change, while large pharmaceutical and corporate entities positioned to capitalize on federal approval stand to gain substantially.

Globally, new interpretations of international drug treaties are reshaping CBD policy and hemp regulation in ways that ripple across the U.S. market. On April 1, a federal program took effect allowing certain healthcare models to furnish up to $500 annually in eligible hemp-derived CBD and low-THC products to approved patients—a meaningful expansion of access that immediately triggered lawsuits from anti-marijuana groups seeking to shut it down. 🚀 THIS IS COOL The program represents a quiet recognition that hemp-derived cannabinoids have genuine therapeutic applications, even as federal classification debates rage. Meanwhile, the U.S. Army announced starting April 20, 2026, individuals with a single cannabis possession conviction can enlist without a waiver—a significant shift for veterans who have long used legal THC products for PTSD and chronic pain management.

💰 MONEY MOVES The cannabis industry continues attracting celebrity capital and mainstream investment. YG Marley is co-founding Young Gong with Glenmere Farms, launching April 19 in New York, while cannabis competition platforms like Proper Doinks are partnering with High Times for future Cannabis Cup activations. Cultural figures including Latin superstar Farruko are reframing cannabis explicitly as medicine and resistance, positioning the plant outside purely commercial frameworks.

A new national Latino cannabis coalition launched March 31, highlighting how communities have shaped reform while remaining excluded from policy and capital decisions. The coalition aims to build organized influence at the intersection of cannabis, immigration, and economic justice—acknowledging that normalization without equitable participation leaves existing power structures intact. 💰 MONEY MOVES This matters financially: cannabis tax revenue in legalized states now funds education, healthcare, and community reinvestment. Who's included in that economy determines who builds generational wealth.

The credibility of federal enforcement agencies continues eroding. The DEA carries documented trails of corruption cases and oversight failures while maintaining influence over how cannabis is scheduled, researched, and regulated nationally. A $10 million payment tied to a Florida Medicaid settlement moved through multiple organizations, eventually funding anti-drug nonprofits—a pattern raising questions about how public health dollars actually flow in prohibition-era bureaucracies. None of this changes federal Schedule I status, but it shapes how enforcement happens on the ground.

Texas remains caught between national momentum and state law. While federal programs expand hemp access and rescheduling discussions continue, Texas hemp regulations and low-THC cannabis policies operate independently of national policy shifts. The state's existing programs serve patients, but the larger question remains: how will Texas respond when federal policy finally moves, and will existing patients and small businesses benefit, or will rescheduling primarily advantage corporations already positioned to scale?